Imagion Biosystems Limited (ASX: IBX) (the Company), is pleased to confirm that the rights associated with the Company’s Renounceable Rights Issue announced on 28 October 2019 have commenced trading on a deferred basis under the ASX ticker IBXR.
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer cells utilising its proprietary MagSense®
We’re on a mission to make cancer more detectable.